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Abstract: Modeling the physiology of the human placenta is still a challenge, despite the great
number of scientific advancements made in the field. Animal models cannot fully replicate the
structure and function of the human placenta and pose ethical and financial hurdles. In addition,
increasingly stricter animal welfare legislation worldwide is incentivizing the use of 3R (reduction,
refinement, replacement) practices. What efforts have been made to develop alternative models
for the placenta so far? How effective are they? How can we improve them to make them more
predictive of human pathophysiology? To address these questions, this review aims at presenting
and discussing the current models used to study phenomena at the placenta level: in vivo, ex vivo,
in vitro and in silico. We describe the main achievements and opportunities for improvement of each
type of model and critically assess their individual and collective impact on the pursuit of predictive
studies of the placenta in line with the 3Rs and European legislation.
Keywords: placenta; organ on a chip; placenta on a chip; 3Rs; in vitro models; in silico models
1. Introduction
The placenta is a unique temporary organ responsible for (1) transferring important
gases and nutrients between mother and fetus, (2) contributing substrates for the fetal
metabolism and removing fetal waste products, (3) producing steroid and peptide hor-
mones (for the circulatory systems of both the fetus and the mother) and (4) acting as
an immunological barrier for the fetus. These are all functions performed by separate
organs in the extrauterine life of humans, showing that this organ performs “physiological
multitasking”. Indeed, in its short existence, the placenta shows remarkable adaptation
and development in response to the changing requirements of the growing fetus [1,2].
The human placenta brings the maternal and fetal circulatory systems into contact
while keeping them independent, due to its intricate structure and adaptation in pregnancy.
The placental barrier, composed essentially of trophoblasts, connective tissue and endothe-
lium, separates the fetal and maternal compartments and is a key structure for this organ’s
function [3,4]. Maternal—fetal exchange takes place in the areas where the barrier is an
extremely thin membrane (only 3.5 µm thick) [2]. The rate and amount of human placental
transfer are determinants for fetal development, and for that reason, the placenta has been
the subject of several studies from different fields. The correct development of the placental
structure and function should be maintained for a healthy pregnancy. Importantly, the
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placenta is permeable to ensure the passage of vital substances (such as nutrients and
oxygen); however, it can also be permeable to other exogenous substances and potentially
harmful chemicals, such as phthalates, phenols (e.g., bisphenol A (BPA)), polychlorinated
biphenyls (PCBs) and heavy metals [5,6].
It is, therefore, crucial to understand placental physiology in humans through the
development of reliable models suitable for testing placental function under a multitude of
different conditions.
A significant number of studies investigating placental physiology and pathology
have focused on animal models and 2D cultures of placental cell lines. Although studies
on these models are valuable to acquire new knowledge, they cannot fully replicate the
structure and function of the human placenta or provide information that is physiologically
relevant to human in vivo placental physiology.
An additional issue with the reliance on animal placental models relates to their ethical
and financial implications. Due to stricter animal welfare legislation in the EU, USA and
other countries worldwide [7,8], there is a significant drive to replace, reduce and refine
(3Rs) the use of animals for scientific purposes. Thus, it is imperative that robust and
sensitive alternative placental models are developed, validated and implemented.
In addition to animal models, there are currently other approaches to model the pla-
centa, including ex vivo, in vitro and in silico methods that have provided useful insights
into the mechanisms of the fetal—placental barrier. However, further advances and new,
more representative models are still needed to better recapitulate the complex architec-
ture and dynamics of the human fetal—placental barrier and provide a more in-depth
understanding of the organ’s function.
Here, we provide an overview of the current placental barrier models available to give
biologists, toxicologists and bioengineers an idea of the landscape of tools and methods at
hand. We discuss their uses and limitations, pointing out how they can be improved and
integrated to design better models with greater predictive value and translational potential
and also impact on the 3Rs.
2. In Vivo Placental Models
With the exception of primates, animal models have been proven to be less than ideal
for the study of human placental physiology, as many aspects, such as the high level of
invasiveness of trophoblasts, are unique to humans [9,10]. Primate pregnancy has been
used as an animal fetal—placental model, as it closely relates to humans in terms of length
of gestation, changes in the contractile milieu, mechanisms of steroidogenesis and process
of placentation, to name a few [11].
Other animal models include sheep, guinea pigs and mice. To date, numerous studies
have used sheep to gather better insight into the functions of fetal-maternal vasculature
with some success [12]. Although the sheep is an excellent model to study placentation,
there are certain differences between sheep and human placentas, including rate of an-
giogenesis, physiological structure and glucose transfer [12,13]. On the other hand, sheep
are fairly large animals, so they require greater resources (i.e., larger housing facilities),
care and experimental considerations. Their gestation period is rather lengthy (~65 days),
which also contributes to financial constraints for such studies [14].
Guinea pig placentas have also been used to investigate how trophoblasts proliferate
and the resemblance in terms of their distribution to the human placenta [15]. Mice too have
been used widely, specifically to study the effects of chemicals in the placenta. However,
the mouse placenta significantly differs from the human organ. For example, in mice, the
definitive structure of the placenta is completed halfway through gestation, and trophoblast
invasion occurs late in gestation. Conversely, in humans, the functional and structural unit
of the placenta is already established 21 days after ovulation, and placental progesterone
production is taken over by the syncytiotrophoblast after 8 weeks [16]. These differences
in morphology and endocrine functions are serious limitations of the mouse model and
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raise several questions concerning the extrapolation of the results to human experimental
studies conducted in rodents.
It should be noted that placental in vivo models have been successfully used to study
pregnancy pathologies or unfavorable conditions. For example, in a study where male
C57BL/6 mice were on a high-fat diet, it was shown that paternal obesity can have adverse
effects before conception, as it appears to change the transcriptome and methylome of the
placenta [17]. This is of increasing importance, given that paternal obesity can adversely
affect fetal development and placental weight [18]. Besides mice, rats, guinea pigs, rabbits
and sheep have been used to study fetal growth restriction (FGR) [19]. Similarly, there
have been a number of preclinical models studying preeclampsia (PE), one of the leading
causes of maternal morbidity and mortality globally [20]. Indeed, numerous animal models
have been used to study consequences for maternal health or therapeutic interventions for
PE [21]. These range from mouse and rodent models to dogs and rhesus monkeys.
The debate as to what is the most appropriate animal model to study placentation
continues. It is evident that every single animal model can provide useful insights, but
issues still remain in terms of absolute resemblance to human pregnancy and anatomical
features (including development) of the fetal—placental unit. Furthermore, the use of
certain animal models involves the need for culling, which raises significant issues in terms
of the principles of the 3Rs. The degree of severity of culling ranges from decapitation to
CO2 asphyxiation and hysterectomy.
Some examples that require this practice involve the testing of endocrine-disrupting
chemicals (EDCs) on mice: a study by Susiarjo and colleagues tested the impact of BPA
on the expression of imprinted genes in the mouse embryo and placenta, with the latter
tissue exhibiting the more significant changes in relation to the control group [22]. For
this study, two strains of pregnant mice (C57BL/6 and B6 CAST7) were sacrificed by CO2
asphyxiation, including the sacrifice of litters. For placental assessment, control and treated
groups consisted of 9–13 mice per group. Moreover, for the fetal experiments, 6 control and
6 exposed fetuses were used per dose [22]. Similarly, using pregnant Sprague—Dawley rats,
the placental transfer of conjugated BPA and subsequent reactivation in the rat fetus have
been studied [23]. After perfusion of the EDC, dams and fetuses (n = 5) were euthanized
by incision of the caudal vena cava, and placentas were collected. In a recent study of the
determination of EDC pharmacokinetics in maternal and fetal rhesus monkeys, fetuses
(n = 5) were extracted and euthanized via a pentobarbital overdose, and placental tissue
was collected [24]. Finally, gestational exposure to BPA in pregnant Suffolk ewes was
investigated where dams were administered a barbiturate overdose and fetuses (n = 5)
were removed for tissue harvest [25]. Based on the findings of the Expert Working Group
on Severity Classification Criteria (conducted in support of the revision of the early EU
Directive 1986/609 on the protection of animals used for scientific purposes), it is evident
that the severity level of animal procedures for EDC testing is moderate but can only be
severe in toxicity testing (high doses) where death is the end-point [26].
In Vivo Metrics—Impact on 3Rs
Despite the serious considerations regarding animal models mentioned in the previous
section, during the past decade (2010–2020), 8830 manuscripts were published using animal
models (ranging from mice and rats to ewes and monkeys) to study placental physiology;
914 were related to preeclampsia, 281 to toxins and 56 to EDCs. Moreover, 211 studies were
focused on umbilical cord physiology (source: PubMed.gov; filters: placenta, 2010–2020,
“other animals” with specified search terms). Validation and development of alternative
3D in vitro models or the use of organotypic cultures of human placenta will have a
measurable impact as a sound alternative for assessing the effects of any molecule on
placental physiology and subsequently contributing towards the 3Rs.
Adoption of alternative models, such as organ-on-a-chip (OOC), human perfused
placentas and placental explants, will inevitably drive a quantifiable reduction in and,
potentially, replacement of the use of animals as part of the 3Rs. Comparative studies
J. Clin. Med. 2021, 10, 3444 4 of 16
between human placental explants or OOC models and in vivo studies will enable minimal
use of animals per experiment, providing there is reproducibility of readouts. It should be
noted that when placental function is assessed in mice or rats, apart from the mothers, all
offspring are culled, leading to an exponential rise in animal usage, as in Susiarjo et al.’s
study cited above [22]. Besides mouse and rat models, placental studies have also used
primates [24]. However, research using nonhuman primates raises serious ethical issues,
as reflected by the EU ban (Directive 2010/63) [27] which states: “the use of nonhuman
primates should be permitted only in those biomedical areas essential for the benefit of
human beings, for which no alternative replacement methods are yet available”. Thus,
in Europe as well as in most countries that are adopting legislation to reduce the use of
animals for scientific purposes, the nonhuman primate model is no longer an option for
studying placental function or structure.
It is expected that OOC models will be used in priority settings during drug devel-
opment and chemical safety assessment, as they will allow the detection and study of
pharmacological and toxicological effects before animal testing is necessary. With the
implementation of robust and representative alternative methods, chemicals can be eval-
uated in more detail than with traditional in vitro systems and reduce the number of
ineffective/toxic chemicals that are taken further to in vivo studies. An area where these
approaches will have minimum impact will be on the third R: refining the way animal
experiments are conducted to ensure minimal suffering.
3. In Vitro Placental Models
3.1. Placental Explants
An alternative to animal models is the use of human placental (villous) explants.
During the past decade (2010–2020), 704 studies were published using human placental
explants (source: PubMed.gov; filters: 2010–2020, human; search terms: placenta explant).
This could be due to the easy accessibility of this particular tissue (most are discarded after
birth) and the advancement of handling techniques in the tissue culture room. Over the past
decade, placental villous explants have been used to study metabolism, syncytialization
processes, endocrine activity and placental transfer/barrier [10]. These include models
of not only term placentas, but also first trimester ones (i.e., 7–12 weeks) where certain
biochemical and morphological changes have been studied, including the release of the key
(for pregnancy) hormone beta human chorionic gonadotrophin (β-hCG) and the uptake
of essential amino acids [28]. In one such first trimester model, the effect of the hypoxic
environment was studied in terms of assessing the frequency and size of extravillous
trophoblast outgrowths [29].
Studies have also used placental explants from complicated pregnancies (i.e., preterm,
preeclampsia, gestational diabetes, intrauterine growth restriction) as models that mimic
the actual milieu of the disorder. For example, using preeclamptic placenta, we have
shown that preeclampsia is associated with impaired regulation of the placental nitric
oxide—cyclic guanosine monophosphate pathway by corticotropin-releasing hormone [30].
With the explosion of the omics and sequencing technologies, a plethora of data has become
available using human placental tissues. Therefore, the entire placental transcriptome has
now been characterized [31]. This is of increasing importance since it can provide crucial
information for molecular mechanisms underlying successful placentation and pregnancy
or detect potential defects at the genomic level associated with some disorders. More
recently, single-cell transcriptomic signatures of human term and preterm placentas have
become available [32]. These single-cell readouts can be used as potential biomarkers for
gynecological diseases.
However, certain challenges still remain with the use of human placental explants.
For example, steroidogenic enzyme activities appear to be reduced in culture, thus creating
issues when using this model to study sex steroids [33,34]. Moreover, there is still some
controversy in terms of the potential impact of labor on placental gene changes. For
example, Cindrova-Davies et al. have argued that apoptotic events are activated in women
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undergoing labor compared to nonlaboring ones, in addition to changes in the expression
of 90 genes and subsequent activation of the NF-κB pathway. They concluded that the
mode of delivery leads to significantly different placental gene expression profiles [35].
The impact of delivery on placental integrity and function is still debatable. For instance,
a study by Sitras and colleagues has concluded that the mode of delivery does not alter
placental gene expression [36].
Perfusion systems were first developed by Panigel in 1967 [37] and were further
developed significantly by Schneider [38,39] to allow maintenance of cotyledon identified
and perfused from recently delivered placenta. They have been used to investigate the
physiology of the placenta and the transfer and metabolism of drugs and nutrients and
to understand the role of environmental cues in fetal diseases [40,41]. Perfusion systems
tend to be used for a short time period, around four to six hours, and can be maintained
for a maximum of 24 h. The parameters of the perfusion systems are both controllable and
measurable: blood flow on both the maternal and fetal side is controllable, pressure can be
measured, the arterial O2 concentration and arterial pH can be determined experimentally,
metabolites can be measured at the venous outlet and diffusion across the placental barrier
can de be determined [42,43]. A new advance in the ex vivo perfusion model has been
recently reported, where [1-13C]pyruvate was used to characterize glucose metabolism by
magnetic resonance imaging (MRI) and by dynamic contrast-enhanced (DCE) imaging
in perfused placentas, highlighting its significant application in the study of placental
metabolism and pregnancy complications [44].
In a systematic review by Hutson and colleagues [42], it was argued that there are
advantages and disadvantages of this method, namely when used to determine placental
drug transfer. For example, the placental perfusion model maintains cellular integrity and
mimics the in vivo milieu, allowing the measurement of drug transfer and metabolism over
time. However, it cannot be used to determine pharmacokinetics in the first trimester,
which is a window of vulnerability for the developing fetus, and the set-up varies between
different laboratories.
3.2. Primary Cultures and Cell Lines
Although studies on placental explants from humans benefit from investigating the
exact tissues and cells needed to understand human placental physiology, these term
placentas represent pathological conditions as mentioned above. Ex vivo perfusion systems
represent the whole system and whilst short-term experiments can be conducted, studies
over a longer time are required to give a greater understanding of the cell—cell communica-
tion. To address these problems, alternative in vitro models using immortalized or primary
human trophoblasts are often the model of choice to study placental function. Indeed, they
are useful for studying organ or tissue function and at the cellular or subcellular scales, as
cells and their organelles can be studied in detail using imaging and molecular techniques.
Human primary trophoblast cells have been used for a number of studies by Albrecht’s
group, including studies on glucose transport [45], secretion of apolipoprotein A1 and E [46]
and cellular distribution of lipoprotein receptors and cholesterol transporters [47]. Other
groups have used these cells for understanding the role of IL-36 in angiogenesis [48] or to
investigate the insulin-induced toxicity and beneficial effects of metformin [49]. Primary
cytotrophoblasts can indeed differentiate into syncytia; however, a major limitation of all
primary cell cultures is that they have a significantly reduced life under tissue culture
conditions. Since primary cells remain viable for a short time, it makes planning long-term
experiments impractical [10].
In order to circumvent small tissue culture time windows, most in vitro studies employ
immortalized trophoblastic cell lines, including ones deriving from choriocarcinoma [50].
Importantly, these cell lines have been used extensively to gain a better insight into tro-
phoblast cell biology and placental development, syncytiotrophoblast formation and en-
docrine activity, as well as immune aspects of the fetal—placental unit [50,51]. For example,
cell lines such as BeWo, JEG-3 and JAr (all tumor cells lines derived from trophoblasts)
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show similar characteristics to primary trophoblasts in terms of hormone secretion (e.g.,
hCG, estrogens and progesterone) [52]. JEG-3 and BeWo cell lines have distinct fusogenic
capacities. The JEG-3 cell line is unable to morphologically differentiate; therefore, it re-
sembles the undifferentiated and hormonally inactive cytotrophoblast cells, making it an
appropriate in vitro model to investigate early placental events [53,54]. Additionally, BeWo
cells retain the ability to form syncytia when being treated with forskolin (an activator
of adenylyl cyclase) or 8-Br-cAMP [10,54,55]. At this stage, the predominant feature of
the human placenta is the hormonally active syncytiotrophoblast layer. The capability of
BeWo cells to differentiate has established these cells as an in vitro model to study placen-
tal physiology including development, immune and endocrine responses and transport
mechanisms [52,54,55].
Another cell line that has been derived from chorionic villi explants transfected with
the SV40 virus is the HTR-8/SVneo. According to the ATCC: “HTR-8/SVneo, cells were
derived by transfecting the cells that grew out of chorionic villi explants of human first-
trimester placenta with the gene encoding for simian virus 40 large T antigen. These cells
exhibit a variety of markers characteristic of extravillous invasive trophoblast cells in situ:
insulin-like growth factor (IGF)-II, NDOG-5, proliferating cell nuclear antigen (PCNA),
human leukocyte antigen framework antigen (W6/32) and a distinct set of integrins”.
During the past decade, 644 studies used BeWo, 539 used HTR-8/SVneo and 648 used
JEG3 cell lines (source: PubMed.gov; filters: 2010–2020; search terms: specified cell type).
Whilst immortalized trophoblastic cell lines are a useful tool, they cannot recapitulate
the earliest phases of development nor model other placental compartments (vascular,
immune, etc.). Therefore, to investigate human trophoblast differentiation, stem cells have
been used [56]. Thomson et al. first reported embryonic stem cells (hESCs) derived from
human blastocysts in 1998. The cells were capable of trophoblast differentiation [57]. The
group went on to demonstrate that hESCs from embryoid bodies could be differentiated
into syncytiotrophoblast-like structures with the influence of bone morphogenetic protein
4 (BMP4), showing the secretion of human chorionic gonadotropin (hCG) [58,59]. As the
use of hESCs is surrounded by ethical debate, induced pluripotent stem cells (iPSCs) are a
promising alternative. Horii et al. have published reproducible models for differentiating
human iPSCs into trophoblasts [60]. More recently, iPSC-derived trophoblasts have been
used to study preeclampsia (PE), demonstrating changes in the syncytialization process, as
well as differential gene expression in response to hypoxia [61]. This study underpins the
utility of human iPSCs in studying placental disorders and gaining a better understanding
of the pathways involved.
3.3. Classical In Vitro Systems: Transwells and Cocultures
A number of in vitro models that can simulate the human fetal—placental barrier have
been developed. Of these, the most commonly used is the Transwell set-up whereby cells
are cultured on a microporous membrane, generally polycarbonate, that separates an apical
and a basal compartment. The system can be employed to study the transport properties of
the trophoblast barrier, and the cell line of choice is BeWo for its ability to form a confluent
layer [62]. Two endothelial cell lines are used for coculture with the trophoblast cell lines for
more complex Transwell experiments, the most common being a pure vascular endothelial
cell line from the human placenta (HPEC) and human umbilical vein endothelial cells
(HUVECs). They are derived through enzymatic perfusion of the term placenta and
postpartum umbilical vein, respectively. As an example, a coculture model comprising
tight layers of BeWo cells and placental endothelial cells has been generated using a 3 µm
porous membrane for translocation studies to predict fetal exposure to nanoparticles [63].
3.4. Advanced In Vitro Systems
Standard cell culture involves seeding cells in monolayers on tissue culture plates
or in transwells. As an alternative, 3D cell models can be used to study human organ
physiology in cell culture, especially in the fields of cancer and toxicology. Extracellular
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parameters are more physiologically relevant in 3D, allowing cells to self-organize and
grow into organoid-like structures [64]. The field of 3D placental models has evolved
rapidly in the past decade, particularly with the discovery of organoids and advancements
in fluidic systems for cell culture. We found 90 reports of 3D placental models in vitro since
2010. About half of them (43) are related to spheroid systems (Figure 1a) while 37 (11 were
reviews) reports describing a microfluidic placenta-on-a-chip (PoC, Figure 1c) device of
some form have been published (source: PubMed.gov; filters: 2010–2020; search terms:
logical combinations of 3D, spheroid, placenta, model, microfluidic).
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3.4.1. Spheroids and Organoids
Spheroid systems (Figure 1a) have been developed since the 1970s; these are clusters of
single cells or cell aggregates grown without the introduction of an extracellular membrane
(ECM) or cell scaffold in low attachment plates. They were originally used to understand
the microenvironment in tumor progression. White et al. showed a placental spheroid
system using JAr cells in 1988 [65]. Also, Wong et al. used the HTR-8/SVneo extravillous
trophoblast cell line to create a spheroid del t show placental invasion [66]. Spheroid
system are the implest of 3D vitro systems to set up and can b useful for drug
discovery, as they provide a more realistic nd physiologically relevant model than 2D
in vitro assays. However, they cannot be maintained in long-term culture, nor are they
suitable for quantitative transport experiments, and they still cannot fully mimic the
complexities of the placenta.
More complex organoid systems involve the 3D culture of one or more types of
mammalian stem cells, thereby replicating early embryogenesis and relying on the cells’
self-organization properties to produce a structure that resembles the key morphological
and functional characteristics of hu an organs [67]. Many studies culturing placental
organoids do so by seeding and mbeddin trophoblasts nto specific cell scaffolds, typi-
cally composed of Matrig l (a gel-like protein mixt secreted by Engelbr th-Holm-Swarm
(EHS) mouse sarcoma cells), allowing the cells to grow in an irregular luminal 3D structure
as shown in Figure 1b. Using this method, a recent study by Haider et al. [68] describes how
the team established a long-term expanding organoid culture from purified first-trimester
cytotrophoblasts (CTBs), where cells could divide and differentiate. More recently, Turco
and colleagues [69] produced long-term fetus-derived trophoblast organoids that differen-
tiated into both syncytiotrophoblast and extravillous trophoblast.
While the results of these studies are highly promising and useful for investigating
placental structure and function, the use of Matrigel and gels such as fibrin [70] or gelatin
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methacrylate [71] as scaffold materials poses some challenges. As they are derived from
animals, they not only pose ethical concerns but also possess a high degree of batch-to-
batch variability.
Recognizing the limitations of the use of Matrigel and other animal-derived gels as
scaffold materials, several research groups are now relying on synthetic or plant-derived
scaffolds, which increase reproducibility and reliability of the model and also address the
3R principles.
For example, we have developed a functional platform based on a 3D culture model
of human placental cells (BeWo) using Growdex, a plant-based hydrogel matrix containing
cellulose. Cells were seeded at 80,000 cells/mL and initially grown for a length of 21 days
(Figure 2a–c). Around day 7, they formed spherical structures with multinucleated surfaces,
resembling syncytiotrophoblast formation. Staining of these structures with E-cadherin
revealed that they acquire an amorphous structure without a defined cell membrane around
cells (Figure 2e). These changes were concomitant with an increase in the syncytialization
marker syncytin-3 (Figure 2d).
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3.4.2. Planar and Organ-on-a-Chip Models
hile the spheroid and organoid and models are of interest for their ability to reca-
pitulate many of the features of a developing placenta, enabling in-depth studies of cell
differentiation and organization, their architecture does not lend them well to investigations
of placental-to-fetal transport. In order to address the complexity of the placental tissue
in a set-up that allows measurements of the translocation of molecules across a barrier,
Nishiguchi et al. [72] developed a 3D Transwell system with BeWo and placental explants
(from the first to third trimester) with HUVECs to recreate the placental barrier in vitro.
Cells were cultured over six days in Matrigel, an expression of E-c dherin was detected.
Transmission electron microscopy and confocal microscopy images showed the fo mation
of microvilli at the apical surface and clear differentiation of cell types, respectively.
Organ-on-a-chip (OOC) systems have been developed over the past decade since
the development of the lung-on-a-chip by Huh et al. [73]. The main structural material
for these microfluidic devices is poly dimethyl siloxane (PDMS). They are engineered by
analyzing the target organ to understand salient parameters of the system, including cell
types present, structural morphology and mechanical and chemical cell signaling cues. The
biological system is then simplified down into key cell types that are cultured in the OOC
system, as illustrated in Figure 1c. The greatest difficulty encountered by researchers is
J. Clin. Med. 2021, 10, 3444 9 of 16
mimicking the complexity of the placental barrier as a dynamic structure in which intrinsic
and extrinsic endocrinal signaling play a crucial role in determining its function.
An example of a simple PoC system where two microfluidic channels were separated
by a vitrified collagen membrane coated with fibronectin and gelatin (Figure 1c) was
provided by Lee and colleagues. Here, human trophoblasts (JEG-3) and GFP expressing
human umbilical vein endothelial cells (HUVECs) were implanted on either side of the
membrane. Following a 2 h incubation, both cell types were perfused with respective
media at 30 µL/h. Fluorescence microscopy images showed that JEG-3 and HUVECs had
merged across the membrane as opposed to forming discrete structures [74].
A similar coculture study was conducted by Blundell et al. using BeWo trophoblasts
and human placental villous endothelial cells (HPVECS) to investigate drug transport
across the placental barrier. Both trophoblasts and HPVECs showed E-cadherin and
vascular endothelial cadherin expression. Transepithelial—endothelial electrical resistance
was measured and showed confluent monolayers had formed at 48 h. FITC-labeled heparin
was inserted into the device to investigate whether the device would mimic the in vivo
placental barrier and prevent the transport of soluble molecules, while drug transport was
analyzed using glyburide [75].
Further PoC systems have been developed using BeWo and HUVECs in PDMS de-
vices using different membranes, including a 0.4 µm pore polyester structure coated with
entactin-collagen IV-laminin to investigate caffeine transfer across the placental barrier [76].
Yin et al. also used BeWo and HUVEC cells; however, they took an alternative approach to
the ECM, using Matrigel as the central scaffold with chitosan on the maternal side of the
device to investigate exposure to TiO2 nanoparticles [77].
Using OOC systems allows the formation of the placental barrier and early experi-
ments investigating the transport of molecules across this crucial interface. It is clear that
BeWo and HUVECs are the most common cell types used to mimic the placental barrier
in vitro in these devices. As discussed, human iPSCs are routinely used to derive placental
organoids. These cells are yet to be seen in more complex organ-on-a-chip systems for the
placenta; however, iPSCs have been used to mimic other organs on a chip, including the
heart, lung, gut and blood—brain barrier [59,78]. The amalgamation of OOC with stem
cell technology will allow the field to move away from immortalized cell lines that do
not mimic the true physiopathology of the placenta and allow for patient-specific chips to
be used for precision medicine. The materials used to fabricate the devices are less clear,
with each lab choosing its own specific ECM. The newer OOC devices are moving towards
synthetic polymers, but proteins such as fibronectin or laminin are required to allow cell
adhesion. PDMS, the main mechanical structure of OOC devices, is known to adsorb drug
compounds. This is an issue, not only for researchers working on drug development and
toxicity testing in placenta models, but also for the whole OOC field. With all polymers,
there are also questions regarding sustainability that must be addressed. Nonetheless,
the OOC models show promise, specifically in the development of placental barriers for
toxicological applications.
4. In Silico Placental Models
In silico models are a useful tool to facilitate the study and prediction of different
aspects of placental physiology and pathology since the organ is unreachable for direct
analysis during pregnancy.
These models bring together the advantages of both in vivo and in vitro experimen-
tation, posing no ethical issues or the high costs associated with in vivo experiments.
Furthermore, they enable the inclusion of an unlimited number of parameters in a single
study, providing results that can relate to a whole organism, unlike in vitro studies [79].
Figure 3 summarizes the three primary types of in silico models.
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physicochemical and structural properties using statistical methods such as multivariate analysis [82].
Despite being a relatively recent field, several types of in silico models have been
developed for the placenta, aiming at recreating both physiological and pathophysiological
scenarios and studying the transfer of substances across the placental barrier. The latter
is a field of application widely explored for developmental and reproductive toxicology
(DART)-related investigations.
The bibliometric analysis of in silico placental modeling in the literature of the past
decade (2010–2020) confirms a relatively low number when compared to the other types
of models. However, it is also evident that the trend has been increasing in the last few
years. It is important to state that, due to the different terms used to describe an in silico
tool/approach, the choice of keywords does not always yield fully representative search
results. Since 2010, 148 studies have been published that rely on the keywords “computa-
tional” + “model” + (“placenta” or “placental”) + (“blood” or “flow” or “vasculature”). On
the other hand, a search in the same time window for “PBPK pregnancy” yields 93 results,
while “PBPK” + “placenta” shows only 26 results. More specifically, if we add the term
“in-silico” to the latter search, seven studies, five of which are from the past 4 years are
identified (source: PubMed.gov). To identify QSAR studies, we used the keywords “QSAR”
+ “placenta” + “transfer”; the search resulted in five relevant publications since 2007 (source:
PubMed.gov; filters: 2010–2020; search terms: as specified).
4.1. Fluid and Structure Interaction Models
Some models simulate the hemodynamics of the placenta, scrutinizing the blood
circulation in different structures ranging from the spiral arteries of the maternal com-
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partment [83] to the terminal villi on the fetal side [84–87]. The simulations are based on
computational fluid dynamics that recreate the vascular structures of the placenta and
model blood flow through them. These allow researchers to understand, for instance,
how the development of the correct geometry of the organ can impact transfer processes,
since the fetal/maternal exchange of crucial substances is determined by the blood flow
of both circulations. Indeed, different flow models address not only the structure and
hemodynamics of the placental tissues but also the diffusion of small solutes, providing an
approach for linking placental structure and function [88].
Computational studies can help understand pathological scenarios, such as the irreg-
ular shape of the placenta or of the villous blood vessels [83,85–87], which are important
aspects for pregnancy outcomes. Another example is the in silico simulation of anomalies in
the architecture of the villous tree [89] and irregular blood flow in the intervillous space [80]
in intrauterine growth restriction (IUGR) placentas.
The placental structure in some of the most recent models is obtained through imag-
ing of the organ after tissue processing with advanced imaging and 3D reconstruction
techniques [90]. Modeling the data gathered through computational simulations allows
a noninvasive and faithful representation of the structure and dynamics of the human
placenta, which cannot be accomplished with in vitro or in vivo models. In a different
perspective, several parameters for the simulations were also acquired from ex vivo studies,
which represents a case of a very profitable synergy between ex vivo and in silico, illustrating
the potential of the 3Rs for placental models.
There is still an issue that most of these in silico models cannot address: the changes
in the placenta during pregnancy, since in most cases the structure can only be recreated
for the term placenta. The dynamic changes in the placenta are perhaps one of the main
challenges not only for in vivo and in vitro models but also for in silico models. Nevertheless,
there are some computational studies that are tailored for different stages of the pregnancy;
such is the case of the studies by Clark et al. [91] and Saghian et al. (2017) [92].
4.2. Models for the Transfer of Xenobiotics
The fetus is exposed not only to endogenous molecules, but also to exogenous ones
that can be potentially toxic. Modeling the transfer, and more generally the absorption,
distribution, metabolism and excretion (ADME), of xenobiotics from the mother to fetus
through the placenta has become one of the efforts in the DART field. To this end, different
in silico approaches have been developed, such as statistics-based QSAR analysis and PBPK
models [61].
There are some excellent recent reviews on placental PBPK models including pla-
centa compartments [81,93] that illustrate that there are different approaches to model
ADME phenomena in pregnancy. Indeed, computational analysis and simulations can
be valid alternative tools for estimating and predicting xenobiotic concentrations in the
placental fetal compartment and/or fetus, which can be accomplished with common sta-
tistical/modeling software such as R [94], MATLAB [95] and Berkeley Madonna [96] and
more specific ones such as the Simcyp Simulator [97], which is specialized in predicting
ADME processes. Usually, the parametrization of such models comes from ex vivo human
placenta perfusion experimental data, while the validation is performed by comparing
predicted values with reported clinical values of maternal, umbilical cord blood and/or
fetal concentrations [94,96,97]. As for computational models, there is an evident advantage
in exploring the crosstalk between ex vivo experiments and in silico analysis to construct
predictive PBPK models.
In these models, placental transfer has been modeled using different therapeutic sub-
stances, specifically antiviral drugs for HIV treatment: tenofovir [94], emtricitabine [94,97],
nevirapine [94], darunavir [96] and the benzodiazepine midazolam [95]. One of the most
promising features of some of the in silico models is that the same model can be used to
predict concentrations of other compounds, by changing drug-related parameters, which
confers versatility and “reusability” hardly attainable with in vivo models.
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We should note that although the current pregnancy PBPK models are powerful
tools, they do not account for the specific characteristics—including changes in expression
patterns and efflux/influx parameters—of the different placental drug transporters. The
integration of this type of information would facilitate the extrapolation of transfer rates
to earlier stages of pregnancy or even to other types of compounds, which could be a
step forward in establishing PBPK mechanistic models as viable placental drug transfer
prediction tools [41].
Another computational approach to model and predict the permeability of the com-
pounds through the placental barrier consists in the use of QSAR models. These models
correlate the structural and chemical properties of the substances with the available bio-
logical data associated with their permeability/clearance across the placenta [98,99]. The
biological data are often obtained from results of ex vivo experiments reported in the litera-
ture [82,100] or from concentrations of compounds found in maternal blood and umbilical
cord [99,101–104]. These QSAR models have analyzed the placental transfer of diverse
substances such as persistent organic pollutants [102], dioxins [102], widespread chem-
icals [82,103,104], therapeutic drugs [82,99,103,104] and even compounds from tocolytic
herbs [101]. As an output of the statistic-derived analysis, the models have also identified
potential molecular characteristics of the different substances that can be determinants for
placental transfer.
QSAR models potentially allow for quicker testing, justifying their increasing popu-
larity in recent years. The possibility to perform high-throughput screening, together with
the availability of comprehensive databases and the possibility of standardization of QSAR
reporting have reinforced the role of the 3Rs for toxicity testing [105]. Nevertheless, the
QSAR models currently available predict the placental transfer rates only at end of the
pregnancy. The future perspective is that of integrating the predictions with a pregnancy
PBPK model that considers the dynamic maternal and fetal toxicokinetics and extrapolates
to the previous gestation stages [81].
5. Future Perspectives
We present an overview of the state of the art in placental models, from in vivo models
to nonanimal technologies, which may be based on ex vivo tissue, cells or even mathematical
models. Despite the well-known species-specific differences in placental development,
in vivo (animal) models continue to dominate the publication landscape. What is apparent
though is the growing trend towards the merging of data from different studies empowered
by using in silico models. Mimicking and predicting placental physiology should improve
greatly from this trend, although support is needed from bioengineering, informatics
and mathematics in a field still very much occupied by experimentalists. For instance,
the estimation of substance concentrations in the different placental/maternal and fetal
compartments is possible due to the computational re-interpretation and analysis of in vivo
and in vitro data. These phenomena are intricately correlated with the structure and
hemodynamics of the placenta, which are aspects that can be retrieved from in vivo and ex
vivo models and be further investigated, again resorting to in silico tools.
The future of 3R-oriented cooperation between nonanimal (in silico and in vitro) models
consists of employing computational tools to simulate and provide the right criteria for
the design of in vitro experiments. Then, closing the circle, analysis of in vitro outcomes
can validate and/or improve in silico modeling and predictions. At the same time, in vitro
models should undergo continuous improvement through the use of 3D cultures and stem
cells. Fluidic devices such as multicompartmental bioreactors or multiorgan chips could
also be used to integrate placental models with fetal tissue models to better replicate the
in vivo milieu. The symbiosis between in silico tools and in vitro methods can be tuned and
optimized, ideally reaching multicompetent systems that can recapitulate placental in vivo
processes without the use of animal models.
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